The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...

Bob Duggan’s success shows you don’t need a Ph.D., or even a college education, to make money in the complex world of biotech ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...